1. Home
  2. Frontier Botanics
  3. Processing & Extraction
Value Capture

Processing & Extraction

The flower is the starting point. The extract is where the value lives.

How the product is processed and sold matters more than how much is grown. Our processing strategy is designed to capture the maximum value from every kilogram of flower.

Pathway

GACP to GMP: The Pathway to Market

Our GACP certification covers the agricultural phase of production. To reach EU pharmacy shelves, product must pass through a GMP-certified processing facility. In the near term, we work with established European GMP-certified processing partners. Our target is to achieve our own EU-GMP certification by the end of 2026 with the completion of our dedicated processing facility — bringing the full value chain in-house.

In place

GACP

Agricultural-phase certification to EU standards.

Near term

Partner GMP processing

Established European GMP-certified processors.

Target · End 2026

Own EU-GMP facility

Dedicated processing facility, value chain in-house.

Commercial model

Toll Processing: Retained Ownership

Instead of selling flower outright to a contract manufacturer, we pay a partner GMP-certified facility to process on a fee basis and retain ownership of the finished product. We then sell directly to German and EU distributors at pharmaceutical wholesale prices. This approximately doubles revenue per batch compared to outright CMO sales. Once our own GMP facility is operational by end of 2026, we capture the full margin in-house.

Outright sale to a contract manufacturer≈ 1×
Toll processing, retained ownership≈ 2×

Illustrative only. Reflects management’s description that retained ownership approximately doubles revenue per batch versus outright CMO sales. Not a forecast.

Product

Rosin: The Solventless Premium

Rosin is extracted using heat and pressure alone, producing a pharmaceutical-grade concentrate with zero residual solvents. It commands a significant premium over dried flower, has a cleaner regulatory profile, and is increasingly preferred by clinicians and patients for formulation into capsules, tinctures and topicals.

Route to market

Distribution Partners

We are in active discussions with established EU GMP-certified processing and distribution partners with proven German market access and multi-market capability. These partnerships provide our route to market while we build towards our own GMP certification.

The flower is the starting point. The extract is where the value lives. Retained ownership is how we keep it.
FAQs

Frequently asked questions

Everything you need to know about Frontier Botanics, our operations, and the investment opportunity. Still have questions? Our team is happy to walk you through the detail.

Get In Touch
Is medical cannabis legal in the UK?

Yes. Medical cannabis has been legal in the UK since November 2018 following changes introduced after high-profile cases like that of Alfie Dingley. However, access is tightly regulated and prescriptions are typically issued by specialist doctors. Frontier Botanics operates fully within UK and international legal frameworks to ensure compliance at every stage of production and distribution.

Why is cultivation based in Lesotho?

Lesotho was the first African nation to legalise medical cannabis cultivation and export, offering a stable regulatory environment, favourable climate, and cost-efficient production conditions. This allows Frontier Botanics to produce high-quality, pharmaceutical-grade cannabis at scale while maintaining competitive pricing for international markets.

What makes Frontier Botanics different from other medical cannabis companies?

Frontier Botanics focuses on vertically integrated operations—from cultivation in Lesotho to distribution in the UK—ensuring full control over quality, compliance, and supply chain efficiency. The company combines pharmaceutical standards with scalable infrastructure, positioning itself to meet growing demand in regulated global markets.

What is the current investment opportunity?

Frontier Botanics is currently raising capital to expand cultivation capacity, enhance processing facilities, and secure additional distribution partnerships. The funding round is designed to accelerate growth, increase production output, and strengthen the company’s position within the rapidly expanding global medical cannabis market.

What is the market potential for medical cannabis?

The global medical cannabis market is projected to grow significantly over the coming decade, driven by increasing legalisation, patient demand, and clinical research. Countries across Europe—including the UK—are gradually expanding access, creating a strong long-term growth opportunity for early-stage, compliant operators like Frontier Botanics.

Invest With Us

Ready to explore the opportunity?

Request the investor information pack or speak directly with the team. Available to eligible High Net Worth and Sophisticated Investors.

CallRequest information